Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to 15.91%.

  • Ani Pharmaceuticals' EBITDA Margin rose 2974.00% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.70%, marking a year-over-year increase of 660.00%. This contributed to the annual value of 1.30% for FY2024, which is 989.00% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' EBITDA Margin is 15.91%, which was up 142.04% from 6.57% recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EBITDA Margin ranged from a high of 27.19% in Q1 2021 and a low of -38.94% during Q4 2021.
  • Its 3-year average for EBITDA Margin is 6.98%, with a median of 9.27% in 2023.
  • Examining YoY changes over the last 5 years, Ani Pharmaceuticals' EBITDA Margin showed a top increase of 4,087bps in 2022 and a maximum decrease of 5,696bps in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' EBITDA Margin (Quarterly) stood at -38.94% in 2021, then spiked by 4,087bps to 1.93% in 2022, then surged by 318bps to 5.11% in 2023, then plummeted by 741bps to -2.30% in 2024, then soared by 2,974bps to 15.91% in 2025.
  • Its EBITDA Margin was 15.91% in Q3 2025, compared to 6.57% in Q2 2025 and 13.29% in Q1 2025.